

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
12 June 2025 (12.06.2025)



(10) International Publication Number
WO 2025/119195 A1

(51) International Patent Classification:

A61K 31/433 (2006.01) *C07D 285/04* (2006.01)
A61K 31/541 (2006.01) *C07D 285/02* (2006.01)
A61K 31/429 (2006.01) *A61P 35/00* (2006.01)

(21) International Application Number:

PCT/CN2024/136593

(22) International Filing Date:

04 December 2024 (04.12.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

PCT/CN2023/137577

08 December 2023 (08.12.2023) CN

(71) Applicant: **DANATLAS PHARMACEUTICALS CO., LTD.** [CN/CN]; Suite 101, Floor 2, Building 2-4A, 7#, Liangshuihe 1st Street, BDA, Daxing District, Beijing 100176 (CN).

(72) Inventors: **ZHOU, Wenlai**; Suite 101, Floor 2, Building 2-4A, 7#, Liangshuihe 1st Street, BDA, Daxing District, Beijing 100176 (CN). **ZHUO, Jincong**; Suite 101, Floor 2, Building 2-4A, 7#, Liangshuihe 1st Street, BDA, Daxing District, Beijing 100176 (CN). **YAN, Dan**; Suite 101, Floor 2, Building 2-4A, 7#, Liangshuihe 1st Street, BDA, Daxing

District, Beijing 100176 (CN). **CHEN, Huixian**; Suite 101, Floor 2, Building 2-4A, 7#, Liangshuihe 1st Street, BDA, Daxing District, Beijing 100176 (CN). **WANG, Bin**; Suite 101, Floor 2, Building 2-4A, 7#, Liangshuihe 1st Street, BDA, Daxing District, Beijing 100176 (CN). **ZHANG, Yan**; Suite 101, Floor 2, Building 2-4A, 7#, Liangshuihe 1st Street, BDA, Daxing District, Beijing 100176 (CN).

(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,

(54) Title: COMBINATION OF POLQ INHIBITOR AND ANTI-CANCER THERAPEUTIC AGENT





Figure 1

(57) Abstract: Provided herein are combination therapies, and methods of treating diseases and/or conditions with combination therapies; wherein the combination can include PolQ inhibitor and a second anti-cancer therapeutic agent; and the PolQ inhibitor is represented by the compounds of Formula (I).

[Continued on next page]

LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*